A rapid and reliable method to generate patient-derived glioblastoma organoids captures the features and diversity of their respective parental tumors to allow for testing personalized therapies correlated to organoid profile and the establishment of a biobank for further basic and translational glioblastoma research.
MYBL2 Drives Prostate Cancer Plasticity / Anjali V. Sheahan, Beatriz German, cancer, Cancer Research Communications, Deborah L Burkhart, Ellis Lab, Hannah E.
Phenotypic plasticity is a recognized mechanism driving therapeutic resistance in prostate cancer (PCa) patients. While underlying molecular causations driving phenotypic plasticity have been identified, therapeutic…
Less than 100 years ago, prostate cancer which attacks a gland that is part of the male sex organ, was seen as a death sentence…
“When I meet patients who tell me: ‘You saved my life,’ it is an unforgettable moment.” Read about laureates James P. Allison and Tasuku Honjo…
Ependymomas are common childhood brain tumours that occur throughout the nervous system, but are most common in the paediatric hindbrain. Current standard therapy comprises surgery…
Join the HJF Team! HJF is seeking a Nurse Practitioner I to support the Murtha Cancer Center Research Program’s (MCCRP) Center for Prostate Disease…
Nature Methods – We developed Significant Latent Factor Interaction Discovery and Exploration (SLIDE), an interpretable machine learning approach that can infer hidden states (latent factors)…
One of Australia’s greatest biomedical research scientists was honored today by giving the Ashley Dunn Oration at the Lorne Cancer conference – Professor…
Shiao et al. reveals the phenotypic and spatial changes that occur in the tumor immune microenvironment following anti-PD-1 therapy and radiation in triple-negative breast cancer. They…
Shiao et al. reveals the phenotypic and spatial changes that occur in the tumor immune microenvironment following anti-PD-1 therapy and radiation in triple-negative breast cancer. They…
